
03 Oct 2023
Allenby Capital: Fusion Antibodies - Finals
Fusion’s FY23 results were in line with revised expectations but are more important as an opportunity to highlight progress of its turnaround strategy. A restructuring, conducted after the May fundraising, is now complete giving Fusion a minimum 15-
month cash runway at its reduced cost base. Although no material new contracts have been disclosed since May, we understand Q1 FY24 revenue was in line with internal expectations and Fusion has executed the first of what it hopes will be a number of ....

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Allenby Capital: Fusion Antibodies - Finals
Fusion Antibodies Plc (FAB:LON) | 6.1 0 0.0% | Mkt Cap: 6.93m
- Published:
03 Oct 2023 -
Author:
Robin Davison | John Savin -
Pages:
4 -
Fusion’s FY23 results were in line with revised expectations but are more important as an opportunity to highlight progress of its turnaround strategy. A restructuring, conducted after the May fundraising, is now complete giving Fusion a minimum 15-
month cash runway at its reduced cost base. Although no material new contracts have been disclosed since May, we understand Q1 FY24 revenue was in line with internal expectations and Fusion has executed the first of what it hopes will be a number of ....